Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel

Biomaterials

Volumn 33, Issue 28, 2012, Pages 6758-6768

  Jain, Sanyog ^a   Kumar, Dinesh ^a   Swarnakar, Nitin K ^a   Thanki, Kaushik ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Antitumor efficacy; Layersomes; Nephrotoxicity; Paclitaxel; Pharmacokinetics; Polyelectrolytes

Indexed keywords

ANIONIC POLYMERS; ANTI-TUMOR EFFICACY; BREAST TUMOR; CATIONIC POLYMERS; CELL LINES; DELIVERABILITY; DRUG RELEASE; ENCAPSULATION EFFICIENCY; FREEZE DRYING; IC50 VALUE; IN-VITRO; IN-VIVO; LAYER-BY-LAYER ASSEMBLIES; LAYERSOMES; MTT ASSAYS; MULTI-LAYERED; NEPHROTOXICITY; ORAL DELIVERY; PACLITAXEL; POLYALLYLAMINE HYDROCHLORIDE; POSITIVE CHARGES; PROCESS VARIABLES; RELEASE PATTERN; STABILITY CONDITION; TUMOR GROWTH;

BIOCHEMISTRY; CELL CULTURE; DRUG PRODUCTS; ENCAPSULATION; OPTIMIZATION; ORGANIC ACIDS; PHARMACOKINETICS; PLASTIC COATINGS; POLYELECTROLYTES; TUMORS; ZETA POTENTIAL;

LIPOSOMES;

DIMETHYLBENZ[A]ANTHRACENE; LIPOSOME; NANOXEL; OCTADECYLAMINE; PACLITAXEL; POLYACRYLIC ACID; POLYALLYLAMINE HYDROCHLORIDE; POLYELECTROLYTE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; ENCAPSULATION; FEMALE; FREEZE DRYING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LOADING DRUG DOSE; LUNG ADENOCARCINOMA; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; STOMACH JUICE; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; FREEZE DRYING; HUMANS; INHIBITORY CONCENTRATION 50; LIPOSOMES; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASMS; PACLITAXEL; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84864013044     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.05.026     Document Type: Article

References (45)

1. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., Arbuck S.G., Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993, 20:1-15.
2. Choi J.S., Jo B.W., Kim Y.C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 2004, 57:313-318.
3. van Hoesel Q.G., Steerenberg P.A., Crommelin D.J., van Dijk A., van Oort W., Klein S., et al. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat. Cancer Res 1984, 44:3698-3705.
4. Gabizon A., Dagan A., Goren D., Barenholz Y., Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 1982, 42:4734-4739.
5. Lasic D.D., Papahadjopoulos D. Medical applications of liposomes 1998, Elsevier Science, Netherlands.
6. Ruysschaert T., Germain M., Gomes J.F., Fournier D., Sukhorukov G.B., Meier W., et al. Liposome-based nanocapsules. IEEE Trans Nanobioscience 2004, 3:49-55.
7. Sulkowski W., Pentak D., Nowak K., Sulkowska A. The influence of temperature, cholesterol content and pH on liposome stability. J Mol Struct 2005, 744:737-747.
8. Werle M., Hironaka K., Takeuchi H., Hoyer H. Development and in vitro characterization of liposomes coated with thiolated poly(acrylic acid) for oral drug delivery. Drug Dev Ind Pharm 2009, 35:209-215.
9. Huang A., Makhlof A., Ping Q., Tozuka Y., Takeuchi H. N-trimethyl chitosan-modified liposomes as carriers for oral delivery of salmon calcitonin. Drug Deliv 2011, 18:562-569.
10. Niu M., Lu Y., Hovgaard L., Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine 2011, 6:1155-1166.
11. Parmentier J., Thewes B., Gropp F., Fricker G. Oral peptide delivery by tetraether lipid liposomes. Int J Pharm 2011, 415:150-157.
12. Ciobanu M., Heurtault B., Schultz P., Ruhlmann C., Muller C.D., Frisch B. Layersome: development and optimization of stable liposomes as drug delivery system. Int J Pharm 2007, 344:154-157.
13. Ariga K., Hill J.P., Ji Q. Layer-by-layer assembly as a versatile bottom-up nanofabrication technique for exploratory research and realistic application. Phys Chem Chem Phys 2007, 9:2319-2340.
14. Jain P., Jain S., Prasad K.N., Jain S.K., Vyas S.P. Polyelectrolyte coated multilayered liposomes (nanocapsules) for the treatment of helicobacter pylori Infection. Mol Pharmaceutics 2009, 6:593-603.
15. Szoka F., Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 1980, 9:467-508.
16. Tsumoto K., Matsuo H., Tomita M., Yoshimura T. Efficient formation of giant liposomes through the gentle hydration of phosphatidylcholine films doped with sugar. Colloid Surf B 2009, 68:98-105.
17. López-Pinto J.M., González-Rodríguez M.L., Rabasco A.M. Effect of cholesterol and ethanol on dermal delivery from DPPC liposomes. Int J Pharm 2005, 298:1-12.
18. Lee S.H., Yoo S.D., Lee K.H. Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J Chromatogr B 1999, 724:357-363.
19. Swarnakar N.K., Jain V., Dubey V., Mishra D., Jain N.K. Enhanced oromucosal delivery of progesterone via hexosomes. Pharm Res 2007, 24:2223-2230.
20. Jain S, Chauhan DS, Jain AK, Swarnakar NK, Harde H, Mahajan RR, et al. Stabilization of the nanodrug delivery systems by lyophilization using universal step-wise freeze drying cycle. Indian Patent Application No 2559/DEL/2011, 2011.
21. Abdelwahed W., Degobert G., Stainmesse S., Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 2006, 58:1688-1713.
22. Vertzoni M., Fotaki N., Nicolaides E., Reppas C., Kostewicz E., Stippler E., et al. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J Pharm Pharmacol 2004, 56:453-462.
23. Cho Y.W., Lee J., Lee S.C., Huh K.M., Park K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release 2004, 97:249-257.
24. Kalaria D.R., Sharma G., Beniwal V., Ravi Kumar M.N. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 2009, 26:492-501.
25. Upadhyay K.K., Bhatt A.N., Mishra A.K., Dwarakanath B.S., Jain S., Schatz C., et al. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly([gamma]-benzyl l-glutamate)-b-hyaluronan polymersomes. Biomaterials 2010, 31:2882-2892.
26. ®) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Release 2001, 76:239-254.
27. Kunstfeld R., Wickenhauser G., Michaelis U., Teifel M., Umek W., Naujoks K., et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 2003, 120:476-482.
28. Wu J., Liu Q., Lee R.J. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm 2006, 316:148-153.
29. Choi B.C., Choi J.S., Han H.K. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int J Pharm 2006, 323:81-85.
30. Jain A.K., Swarnakar N.K., Godugu C., Singh R.P., Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 2011, 32:503-515.
31. Cassidy J., Dirix L., Bissett D., Reigner B., Griffin T., Allman D., et al. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998, 4:2755-2761.
32. Socaciu C., Jessel R., Diehl H.A. Competitive carotenoid and cholesterol incorporation into liposomes: effects on membrane phase transition, fluidity, polarity and anisotropy. Chem Phys Lipids 2000, 106:79-88.
33. Chou T.H., Chu I. Interaction of paclitaxel with DSPC in monolayers at the air/water interface at different temperatures. Colloid Surf B 2002, 25:147-155.
34. Mei L., Sun H., Song C. Local delivery of modified paclitaxel loaded poly (ε caprolactone)/pluronic F68 nanoparticles for long term inhibition of hyperplasia. J Pharm Sci 2009, 98:2040-2050.
35. Arien A., Goigoux C., Baquey C., Dupuy B. Study of in vitro and in vivo stability of liposomes loaded with calcitonin or indium in the gastrointestinal tract. Life Sci 1993, 53:1279-1290.
36. Rudra A., Deepa R.M., Ghosh M.K., Ghosh S., Mukherjee B. Doxorubicin-loaded phosphatidylethanolamine-conjugated nanoliposomes: in vitro characterization and their accumulation in liver, kidneys, and lungs in rats. Int J Nanomedicine 2010, 5:811-823.
37. Pandita D., Ahuja A., Velpandian T., Lather V., Dutta T., Khar R.K. Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique. Pharmazie 2009, 64:301-310.
38. Roger E., Lagarce F., Garcion E., Benoit J.P. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release 2009, 140:174-181.
39. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K.F., et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by p-glycoprotein in the intestine. P Natl Acad Sci-USA 1997, 94:2031-2035.
40. Tiwari S.B., Amiji M.M. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol 2006, 9:3215-3221.
41. ®, a novel cremophor free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006, 17:1263-1268.
42. Rabah S.O. Acute taxol nephrotoxicity: histological and ultrastructural studies of mice kidney parenchyma. Saudi J Biol Sci 2010, 17:105-114.
43. Merouani A., Davidson S.A., Schrier R.W. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Am J Nephrol 1997, 17:53-58.
44. Ermolaeva L., Dubskaya T.Y., Fomina T.I., Vetoshkina T.V., Gol'dberg V.E. Toxic effect of an antitumor drug paclitaxel on morphofunctional characteristics of the liver in rats. B Exp Biol Med 2008, 145:263-265.
45. Yeh T.K., Lu Z., Wientjes M.G., Au J.L.S. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 2005, 22:867-874.